Harrow Health Inc. (HROW)
30.00
1.59 (5.60%)
At close: Mar 24, 2025, 3:59 PM
30.25
0.81%
After-hours: Mar 24, 2025, 07:56 PM EDT
5.60% (1D)
| Bid | 29.57 |
| Market Cap | 1.07B |
| Revenue (ttm) | 168.72M |
| Net Income (ttm) | -33.32M |
| EPS (ttm) | -0.95 |
| PE Ratio (ttm) | -31.58 |
| Forward PE | 36.95 |
| Analyst | Strong Buy |
| Ask | 30.92 |
| Volume | 719,390 |
| Avg. Volume (20D) | 413,400 |
| Open | 28.94 |
| Previous Close | 28.41 |
| Day's Range | 28.41 - 30.57 |
| 52-Week Range | 9.86 - 59.23 |
| Beta | 0.69 |
About HROW
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharma...
Sector Healthcare
IPO Date Sep 28, 2007
Employees 315
Stock Exchange NASDAQ
Ticker Symbol HROW
Website https://www.harrowinc.com
Analyst Forecast
According to 4 analyst ratings, the average rating for HROW stock is "Strong Buy." The 12-month stock price forecast is $56, which is an increase of 86.64% from the latest price.
Stock ForecastsNext Earnings Release
Harrow Health Inc. is scheduled to release its earnings on Apr 7, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 days ago
+15.69%
Harrow shares are trading higher on possible conti...
Unlock content with
Pro Subscription
4 months ago
-17.26%
Harrow shares are trading lower after the company reported worse-than-expected Q3 sales results.
